nodes	percent_of_prediction	percent_of_DWPC	metapath
Treprostinil—CYP2C9—Capecitabine—esophageal cancer	0.0947	0.665	CbGbCtD
Treprostinil—CYP2C9—Cisplatin—esophageal cancer	0.0477	0.335	CbGbCtD
Treprostinil—Infusion site pain—Capecitabine—esophageal cancer	0.0178	0.0676	CcSEcCtD
Treprostinil—P2RY12—epithelium—esophageal cancer	0.0104	0.196	CbGeAlD
Treprostinil—Pain in jaw—Capecitabine—esophageal cancer	0.00896	0.034	CcSEcCtD
Treprostinil—PTGIR—epithelium—esophageal cancer	0.00662	0.125	CbGeAlD
Treprostinil—PPARD—digestive system—esophageal cancer	0.00656	0.124	CbGeAlD
Treprostinil—PTGIR—smooth muscle tissue—esophageal cancer	0.00638	0.12	CbGeAlD
Treprostinil—PPARD—lung—esophageal cancer	0.00548	0.103	CbGeAlD
Treprostinil—PTGIR—digestive system—esophageal cancer	0.00504	0.0949	CbGeAlD
Treprostinil—Infection—Carboplatin—esophageal cancer	0.00478	0.0182	CcSEcCtD
Treprostinil—Haematoma—Capecitabine—esophageal cancer	0.00464	0.0176	CcSEcCtD
Treprostinil—Cellulitis—Cisplatin—esophageal cancer	0.00435	0.0165	CcSEcCtD
Treprostinil—Pharyngolaryngeal pain—Capecitabine—esophageal cancer	0.00432	0.0164	CcSEcCtD
Treprostinil—Laryngeal pain—Capecitabine—esophageal cancer	0.00428	0.0163	CcSEcCtD
Treprostinil—PTGIR—lung—esophageal cancer	0.00421	0.0793	CbGeAlD
Treprostinil—Pain—Carboplatin—esophageal cancer	0.00412	0.0157	CcSEcCtD
Treprostinil—Haemoptysis—Capecitabine—esophageal cancer	0.00394	0.015	CcSEcCtD
Treprostinil—Wheezing—Cisplatin—esophageal cancer	0.00385	0.0146	CcSEcCtD
Treprostinil—Body temperature increased—Carboplatin—esophageal cancer	0.00381	0.0145	CcSEcCtD
Treprostinil—PPARD—lymph node—esophageal cancer	0.00375	0.0706	CbGeAlD
Treprostinil—Hypoxia—Methotrexate—esophageal cancer	0.00342	0.013	CcSEcCtD
Treprostinil—Contusion—Capecitabine—esophageal cancer	0.00335	0.0127	CcSEcCtD
Treprostinil—Rectal haemorrhage—Capecitabine—esophageal cancer	0.00323	0.0123	CcSEcCtD
Treprostinil—Cellulitis—Capecitabine—esophageal cancer	0.00321	0.0122	CcSEcCtD
Treprostinil—Cardiac failure congestive—Cisplatin—esophageal cancer	0.00317	0.012	CcSEcCtD
Treprostinil—Bone pain—Capecitabine—esophageal cancer	0.00305	0.0116	CcSEcCtD
Treprostinil—Neck pain—Capecitabine—esophageal cancer	0.00295	0.0112	CcSEcCtD
Treprostinil—Pulmonary embolism—Capecitabine—esophageal cancer	0.00292	0.0111	CcSEcCtD
Treprostinil—PTGIR—lymph node—esophageal cancer	0.00288	0.0542	CbGeAlD
Treprostinil—Melaena—Capecitabine—esophageal cancer	0.00285	0.0108	CcSEcCtD
Treprostinil—Dehydration—Cisplatin—esophageal cancer	0.00267	0.0102	CcSEcCtD
Treprostinil—Ecchymosis—Capecitabine—esophageal cancer	0.00264	0.01	CcSEcCtD
Treprostinil—Hypokalaemia—Cisplatin—esophageal cancer	0.00262	0.00994	CcSEcCtD
Treprostinil—Sepsis—Capecitabine—esophageal cancer	0.00253	0.00963	CcSEcCtD
Treprostinil—Thrombophlebitis—Capecitabine—esophageal cancer	0.00245	0.0093	CcSEcCtD
Treprostinil—Abdominal discomfort—Cisplatin—esophageal cancer	0.00238	0.00905	CcSEcCtD
Treprostinil—Pulmonary embolism—Methotrexate—esophageal cancer	0.00217	0.00826	CcSEcCtD
Treprostinil—Cardiac failure—Capecitabine—esophageal cancer	0.00217	0.00825	CcSEcCtD
Treprostinil—Melaena—Methotrexate—esophageal cancer	0.00212	0.00807	CcSEcCtD
Treprostinil—Pain in extremity—Capecitabine—esophageal cancer	0.00212	0.00805	CcSEcCtD
Treprostinil—Bradycardia—Cisplatin—esophageal cancer	0.00202	0.00769	CcSEcCtD
Treprostinil—Dehydration—Capecitabine—esophageal cancer	0.00197	0.00749	CcSEcCtD
Treprostinil—Ecchymosis—Methotrexate—esophageal cancer	0.00196	0.00747	CcSEcCtD
Treprostinil—Hypokalaemia—Capecitabine—esophageal cancer	0.00193	0.00733	CcSEcCtD
Treprostinil—Sepsis—Methotrexate—esophageal cancer	0.00189	0.00717	CcSEcCtD
Treprostinil—Flushing—Cisplatin—esophageal cancer	0.00185	0.00701	CcSEcCtD
Treprostinil—Influenza—Capecitabine—esophageal cancer	0.00183	0.00696	CcSEcCtD
Treprostinil—Thrombophlebitis—Methotrexate—esophageal cancer	0.00182	0.00692	CcSEcCtD
Treprostinil—CYP2C9—digestive system—esophageal cancer	0.0018	0.0339	CbGeAlD
Treprostinil—Bronchitis—Capecitabine—esophageal cancer	0.00176	0.00669	CcSEcCtD
Treprostinil—Abdominal discomfort—Capecitabine—esophageal cancer	0.00176	0.00667	CcSEcCtD
Treprostinil—Erythema—Cisplatin—esophageal cancer	0.00173	0.00658	CcSEcCtD
Treprostinil—Muscle spasms—Cisplatin—esophageal cancer	0.00166	0.00632	CcSEcCtD
Treprostinil—Pneumonia—Capecitabine—esophageal cancer	0.00164	0.00624	CcSEcCtD
Treprostinil—Depression—Capecitabine—esophageal cancer	0.00163	0.00619	CcSEcCtD
Treprostinil—Ill-defined disorder—Cisplatin—esophageal cancer	0.00161	0.0061	CcSEcCtD
Treprostinil—Anaemia—Cisplatin—esophageal cancer	0.0016	0.00608	CcSEcCtD
Treprostinil—Urinary tract infection—Capecitabine—esophageal cancer	0.00159	0.00603	CcSEcCtD
Treprostinil—Malaise—Cisplatin—esophageal cancer	0.00156	0.00593	CcSEcCtD
Treprostinil—Haematuria—Capecitabine—esophageal cancer	0.00156	0.00592	CcSEcCtD
Treprostinil—Epistaxis—Capecitabine—esophageal cancer	0.00154	0.00585	CcSEcCtD
Treprostinil—Bradycardia—Capecitabine—esophageal cancer	0.00149	0.00567	CcSEcCtD
Treprostinil—Myalgia—Cisplatin—esophageal cancer	0.00147	0.0056	CcSEcCtD
Treprostinil—Haemoglobin—Capecitabine—esophageal cancer	0.00147	0.0056	CcSEcCtD
Treprostinil—Rhinitis—Capecitabine—esophageal cancer	0.00147	0.00558	CcSEcCtD
Treprostinil—Anxiety—Cisplatin—esophageal cancer	0.00147	0.00558	CcSEcCtD
Treprostinil—Haemorrhage—Capecitabine—esophageal cancer	0.00147	0.00557	CcSEcCtD
Treprostinil—Discomfort—Cisplatin—esophageal cancer	0.00146	0.00553	CcSEcCtD
Treprostinil—Pharyngitis—Capecitabine—esophageal cancer	0.00145	0.00553	CcSEcCtD
Treprostinil—Oedema peripheral—Capecitabine—esophageal cancer	0.00144	0.00549	CcSEcCtD
Treprostinil—Oedema—Cisplatin—esophageal cancer	0.00141	0.00537	CcSEcCtD
Treprostinil—Infection—Cisplatin—esophageal cancer	0.0014	0.00533	CcSEcCtD
Treprostinil—Thrombocytopenia—Cisplatin—esophageal cancer	0.00138	0.00526	CcSEcCtD
Treprostinil—Tachycardia—Cisplatin—esophageal cancer	0.00138	0.00524	CcSEcCtD
Treprostinil—Flushing—Capecitabine—esophageal cancer	0.00136	0.00517	CcSEcCtD
Treprostinil—Anorexia—Cisplatin—esophageal cancer	0.00135	0.00512	CcSEcCtD
Treprostinil—Hypotension—Cisplatin—esophageal cancer	0.00132	0.00502	CcSEcCtD
Treprostinil—Abdominal discomfort—Methotrexate—esophageal cancer	0.00131	0.00497	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00129	0.00489	CcSEcCtD
Treprostinil—Erythema—Capecitabine—esophageal cancer	0.00128	0.00485	CcSEcCtD
Treprostinil—Paraesthesia—Cisplatin—esophageal cancer	0.00127	0.00482	CcSEcCtD
Treprostinil—Dyspnoea—Cisplatin—esophageal cancer	0.00126	0.00479	CcSEcCtD
Treprostinil—Back pain—Capecitabine—esophageal cancer	0.00123	0.00469	CcSEcCtD
Treprostinil—Decreased appetite—Cisplatin—esophageal cancer	0.00123	0.00467	CcSEcCtD
Treprostinil—Muscle spasms—Capecitabine—esophageal cancer	0.00123	0.00466	CcSEcCtD
Treprostinil—Pneumonia—Methotrexate—esophageal cancer	0.00122	0.00465	CcSEcCtD
Treprostinil—Depression—Methotrexate—esophageal cancer	0.00121	0.00461	CcSEcCtD
Treprostinil—Pain—Cisplatin—esophageal cancer	0.00121	0.00459	CcSEcCtD
Treprostinil—Ill-defined disorder—Capecitabine—esophageal cancer	0.00118	0.0045	CcSEcCtD
Treprostinil—Anaemia—Capecitabine—esophageal cancer	0.00118	0.00448	CcSEcCtD
Treprostinil—Feeling abnormal—Cisplatin—esophageal cancer	0.00116	0.00442	CcSEcCtD
Treprostinil—Haematuria—Methotrexate—esophageal cancer	0.00116	0.0044	CcSEcCtD
Treprostinil—Malaise—Capecitabine—esophageal cancer	0.00115	0.00437	CcSEcCtD
Treprostinil—Epistaxis—Methotrexate—esophageal cancer	0.00115	0.00436	CcSEcCtD
Treprostinil—Syncope—Capecitabine—esophageal cancer	0.00114	0.00435	CcSEcCtD
Treprostinil—Palpitations—Capecitabine—esophageal cancer	0.00113	0.00429	CcSEcCtD
Treprostinil—Loss of consciousness—Capecitabine—esophageal cancer	0.00112	0.00426	CcSEcCtD
Treprostinil—Body temperature increased—Cisplatin—esophageal cancer	0.00112	0.00424	CcSEcCtD
Treprostinil—Cough—Capecitabine—esophageal cancer	0.00111	0.00423	CcSEcCtD
Treprostinil—Haemoglobin—Methotrexate—esophageal cancer	0.0011	0.00417	CcSEcCtD
Treprostinil—Haemorrhage—Methotrexate—esophageal cancer	0.00109	0.00415	CcSEcCtD
Treprostinil—Arthralgia—Capecitabine—esophageal cancer	0.00109	0.00413	CcSEcCtD
Treprostinil—Chest pain—Capecitabine—esophageal cancer	0.00109	0.00413	CcSEcCtD
Treprostinil—Myalgia—Capecitabine—esophageal cancer	0.00109	0.00413	CcSEcCtD
Treprostinil—Pharyngitis—Methotrexate—esophageal cancer	0.00108	0.00412	CcSEcCtD
Treprostinil—Anxiety—Capecitabine—esophageal cancer	0.00108	0.00411	CcSEcCtD
Treprostinil—Discomfort—Capecitabine—esophageal cancer	0.00107	0.00408	CcSEcCtD
Treprostinil—Oedema—Capecitabine—esophageal cancer	0.00104	0.00396	CcSEcCtD
Treprostinil—Infection—Capecitabine—esophageal cancer	0.00103	0.00393	CcSEcCtD
Treprostinil—Shock—Capecitabine—esophageal cancer	0.00102	0.00389	CcSEcCtD
Treprostinil—Thrombocytopenia—Capecitabine—esophageal cancer	0.00102	0.00387	CcSEcCtD
Treprostinil—Tachycardia—Capecitabine—esophageal cancer	0.00102	0.00386	CcSEcCtD
Treprostinil—Asthenia—Cisplatin—esophageal cancer	0.00101	0.00385	CcSEcCtD
Treprostinil—Anorexia—Capecitabine—esophageal cancer	0.000993	0.00377	CcSEcCtD
Treprostinil—Hypotension—Capecitabine—esophageal cancer	0.000973	0.0037	CcSEcCtD
Treprostinil—Diarrhoea—Cisplatin—esophageal cancer	0.000967	0.00367	CcSEcCtD
Treprostinil—Erythema—Methotrexate—esophageal cancer	0.00095	0.00361	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000949	0.00361	CcSEcCtD
Treprostinil—Insomnia—Capecitabine—esophageal cancer	0.000942	0.00358	CcSEcCtD
Treprostinil—Paraesthesia—Capecitabine—esophageal cancer	0.000935	0.00355	CcSEcCtD
Treprostinil—Dyspnoea—Capecitabine—esophageal cancer	0.000928	0.00353	CcSEcCtD
Treprostinil—Back pain—Methotrexate—esophageal cancer	0.000919	0.00349	CcSEcCtD
Treprostinil—Dyspepsia—Capecitabine—esophageal cancer	0.000917	0.00348	CcSEcCtD
Treprostinil—P2RY12—Hemostasis—HSPA5—esophageal cancer	0.00091	0.00168	CbGpPWpGaD
Treprostinil—Decreased appetite—Capecitabine—esophageal cancer	0.000905	0.00344	CcSEcCtD
Treprostinil—Vomiting—Cisplatin—esophageal cancer	0.000898	0.00341	CcSEcCtD
Treprostinil—Fatigue—Capecitabine—esophageal cancer	0.000898	0.00341	CcSEcCtD
Treprostinil—PTGIR—GPCR ligand binding—GHRL—esophageal cancer	0.000892	0.00165	CbGpPWpGaD
Treprostinil—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000891	0.00165	CbGpPWpGaD
Treprostinil—Rash—Cisplatin—esophageal cancer	0.000891	0.00339	CcSEcCtD
Treprostinil—Pain—Capecitabine—esophageal cancer	0.000891	0.00338	CcSEcCtD
Treprostinil—Dermatitis—Cisplatin—esophageal cancer	0.00089	0.00338	CcSEcCtD
Treprostinil—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000886	0.00164	CbGpPWpGaD
Treprostinil—Ill-defined disorder—Methotrexate—esophageal cancer	0.000881	0.00335	CcSEcCtD
Treprostinil—Anaemia—Methotrexate—esophageal cancer	0.000878	0.00334	CcSEcCtD
Treprostinil—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000875	0.00162	CbGpPWpGaD
Treprostinil—Feeling abnormal—Capecitabine—esophageal cancer	0.000858	0.00326	CcSEcCtD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000857	0.00158	CbGpPWpGaD
Treprostinil—Malaise—Methotrexate—esophageal cancer	0.000857	0.00326	CcSEcCtD
Treprostinil—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000852	0.00324	CcSEcCtD
Treprostinil—PPARD—Generic Transcription Pathway—NOTCH2—esophageal cancer	0.00085	0.00157	CbGpPWpGaD
Treprostinil—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000845	0.00156	CbGpPWpGaD
Treprostinil—Nausea—Cisplatin—esophageal cancer	0.000839	0.00319	CcSEcCtD
Treprostinil—PTGIR—Hemostasis—HSPA5—esophageal cancer	0.000837	0.00155	CbGpPWpGaD
Treprostinil—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000833	0.00154	CbGpPWpGaD
Treprostinil—Cough—Methotrexate—esophageal cancer	0.000829	0.00315	CcSEcCtD
Treprostinil—Abdominal pain—Capecitabine—esophageal cancer	0.000823	0.00313	CcSEcCtD
Treprostinil—Body temperature increased—Capecitabine—esophageal cancer	0.000823	0.00313	CcSEcCtD
Treprostinil—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000822	0.00152	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—CA1—esophageal cancer	0.000815	0.00151	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—SLC10A2—esophageal cancer	0.000815	0.00151	CbGpPWpGaD
Treprostinil—CYP2C9—Biological oxidations—ADH7—esophageal cancer	0.000815	0.00151	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—AKAP13—esophageal cancer	0.00081	0.0015	CbGpPWpGaD
Treprostinil—Arthralgia—Methotrexate—esophageal cancer	0.000809	0.00307	CcSEcCtD
Treprostinil—Myalgia—Methotrexate—esophageal cancer	0.000809	0.00307	CcSEcCtD
Treprostinil—Chest pain—Methotrexate—esophageal cancer	0.000809	0.00307	CcSEcCtD
Treprostinil—Discomfort—Methotrexate—esophageal cancer	0.000799	0.00304	CcSEcCtD
Treprostinil—PPARD—Wnt Signaling Pathway and Pluripotency—TP53—esophageal cancer	0.000773	0.00143	CbGpPWpGaD
Treprostinil—Infection—Methotrexate—esophageal cancer	0.00077	0.00293	CcSEcCtD
Treprostinil—Thrombocytopenia—Methotrexate—esophageal cancer	0.000759	0.00288	CcSEcCtD
Treprostinil—P2RY12—Signaling Pathways—KMT2D—esophageal cancer	0.000757	0.0014	CbGpPWpGaD
Treprostinil—Asthenia—Capecitabine—esophageal cancer	0.000747	0.00284	CcSEcCtD
Treprostinil—PTGIR—GPCR downstream signaling—AKAP13—esophageal cancer	0.000746	0.00138	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—CA2—esophageal cancer	0.000746	0.00138	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—PDE4D—esophageal cancer	0.000741	0.00137	CbGpPWpGaD
Treprostinil—PPARD—Ectoderm Differentiation—MYC—esophageal cancer	0.000739	0.00137	CbGpPWpGaD
Treprostinil—Anorexia—Methotrexate—esophageal cancer	0.000739	0.00281	CcSEcCtD
Treprostinil—Pruritus—Capecitabine—esophageal cancer	0.000737	0.0028	CcSEcCtD
Treprostinil—P2RY12—Signaling by GPCR—AKAP13—esophageal cancer	0.000736	0.00136	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000729	0.00135	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—NR1I2—esophageal cancer	0.000727	0.00134	CbGpPWpGaD
Treprostinil—Hypotension—Methotrexate—esophageal cancer	0.000724	0.00275	CcSEcCtD
Treprostinil—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000718	0.00133	CbGpPWpGaD
Treprostinil—CYP2C9—Biological oxidations—ADH1B—esophageal cancer	0.000715	0.00132	CbGpPWpGaD
Treprostinil—PPARD—Generic Transcription Pathway—SMAD4—esophageal cancer	0.000714	0.00132	CbGpPWpGaD
Treprostinil—Diarrhoea—Capecitabine—esophageal cancer	0.000713	0.00271	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000706	0.00268	CcSEcCtD
Treprostinil—P2RY12—GPCR downstream signaling—GNG7—esophageal cancer	0.000705	0.0013	CbGpPWpGaD
Treprostinil—Insomnia—Methotrexate—esophageal cancer	0.000701	0.00266	CcSEcCtD
Treprostinil—PTGIR—Signaling Pathways—KMT2D—esophageal cancer	0.000697	0.00129	CbGpPWpGaD
Treprostinil—Paraesthesia—Methotrexate—esophageal cancer	0.000696	0.00265	CcSEcCtD
Treprostinil—PPARD—Metabolism—PLCE1—esophageal cancer	0.000693	0.00128	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—ADH7—esophageal cancer	0.000693	0.00128	CbGpPWpGaD
Treprostinil—Dyspnoea—Methotrexate—esophageal cancer	0.000691	0.00263	CcSEcCtD
Treprostinil—Dizziness—Capecitabine—esophageal cancer	0.000689	0.00262	CcSEcCtD
Treprostinil—PPARD—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—esophageal cancer	0.000686	0.00127	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000685	0.00127	CbGpPWpGaD
Treprostinil—Dyspepsia—Methotrexate—esophageal cancer	0.000682	0.00259	CcSEcCtD
Treprostinil—PTGIR—GPCR downstream signaling—PDE4D—esophageal cancer	0.000682	0.00126	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—AKAP13—esophageal cancer	0.000677	0.00125	CbGpPWpGaD
Treprostinil—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000676	0.00125	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—ADCYAP1—esophageal cancer	0.000675	0.00125	CbGpPWpGaD
Treprostinil—Decreased appetite—Methotrexate—esophageal cancer	0.000674	0.00256	CcSEcCtD
Treprostinil—P2RY12—Hemostasis—ABL1—esophageal cancer	0.000674	0.00124	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—PDE4D—esophageal cancer	0.000673	0.00124	CbGpPWpGaD
Treprostinil—Fatigue—Methotrexate—esophageal cancer	0.000668	0.00254	CcSEcCtD
Treprostinil—CYP2C9—Biological oxidations—CYP26A1—esophageal cancer	0.000664	0.00123	CbGpPWpGaD
Treprostinil—Pain—Methotrexate—esophageal cancer	0.000663	0.00252	CcSEcCtD
Treprostinil—Vomiting—Capecitabine—esophageal cancer	0.000662	0.00252	CcSEcCtD
Treprostinil—Rash—Capecitabine—esophageal cancer	0.000657	0.0025	CcSEcCtD
Treprostinil—Dermatitis—Capecitabine—esophageal cancer	0.000656	0.00249	CcSEcCtD
Treprostinil—CYP2C9—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000655	0.00121	CbGpPWpGaD
Treprostinil—Headache—Capecitabine—esophageal cancer	0.000652	0.00248	CcSEcCtD
Treprostinil—PTGIR—GPCR downstream signaling—GNG7—esophageal cancer	0.000649	0.0012	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—GNG7—esophageal cancer	0.00064	0.00118	CbGpPWpGaD
Treprostinil—Feeling abnormal—Methotrexate—esophageal cancer	0.000639	0.00243	CcSEcCtD
Treprostinil—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000634	0.00241	CcSEcCtD
Treprostinil—PPARD—Gene Expression—HIST1H2BM—esophageal cancer	0.000624	0.00115	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—CXCL2—esophageal cancer	0.000621	0.00115	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—ADCYAP1—esophageal cancer	0.000621	0.00115	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—ABL1—esophageal cancer	0.00062	0.00115	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—PDE4D—esophageal cancer	0.00062	0.00114	CbGpPWpGaD
Treprostinil—Nausea—Capecitabine—esophageal cancer	0.000619	0.00235	CcSEcCtD
Treprostinil—CYP2C9—Biological oxidations—GSTO1—esophageal cancer	0.000618	0.00114	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—WWOX—esophageal cancer	0.000617	0.00114	CbGpPWpGaD
Treprostinil—Body temperature increased—Methotrexate—esophageal cancer	0.000613	0.00233	CcSEcCtD
Treprostinil—Abdominal pain—Methotrexate—esophageal cancer	0.000613	0.00233	CcSEcCtD
Treprostinil—CYP2C9—Metapathway biotransformation—GSTO1—esophageal cancer	0.000609	0.00113	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—ADH1B—esophageal cancer	0.000608	0.00112	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—GNG7—esophageal cancer	0.000589	0.00109	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—FKBP1A—esophageal cancer	0.000587	0.00108	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—TYMP—esophageal cancer	0.000581	0.00107	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—ANXA1—esophageal cancer	0.000578	0.00107	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—WIF1—esophageal cancer	0.000574	0.00106	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—CXCL2—esophageal cancer	0.000572	0.00106	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—WWOX—esophageal cancer	0.000568	0.00105	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—CYP26A1—esophageal cancer	0.000565	0.00104	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—CXCL2—esophageal cancer	0.000564	0.00104	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—SST—esophageal cancer	0.000562	0.00104	CbGpPWpGaD
Treprostinil—Asthenia—Methotrexate—esophageal cancer	0.000556	0.00211	CcSEcCtD
Treprostinil—PPARD—Metabolism—ALOX15—esophageal cancer	0.000551	0.00102	CbGpPWpGaD
Treprostinil—Pruritus—Methotrexate—esophageal cancer	0.000548	0.00208	CcSEcCtD
Treprostinil—P2RY12—GPCR downstream signaling—GHRL—esophageal cancer	0.000547	0.00101	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—FKBP1A—esophageal cancer	0.00054	0.000998	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—ANXA1—esophageal cancer	0.000531	0.000982	CbGpPWpGaD
Treprostinil—Diarrhoea—Methotrexate—esophageal cancer	0.00053	0.00202	CcSEcCtD
Treprostinil—P2RY12—Signaling Pathways—CSNK1A1—esophageal cancer	0.000529	0.000978	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—WIF1—esophageal cancer	0.000528	0.000975	CbGpPWpGaD
Treprostinil—PPARD—Generic Transcription Pathway—NOTCH1—esophageal cancer	0.000526	0.000972	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—GSTO1—esophageal cancer	0.000525	0.000971	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—TPI1—esophageal cancer	0.000525	0.000971	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—ANXA1—esophageal cancer	0.000524	0.000969	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—CXCL2—esophageal cancer	0.000519	0.000959	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—SST—esophageal cancer	0.000517	0.000955	CbGpPWpGaD
Treprostinil—Dizziness—Methotrexate—esophageal cancer	0.000513	0.00195	CcSEcCtD
Treprostinil—P2RY12—Signaling by GPCR—SST—esophageal cancer	0.00051	0.000942	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—GHRL—esophageal cancer	0.000504	0.000931	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—ALDOB—esophageal cancer	0.000504	0.000931	CbGpPWpGaD
Treprostinil—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	0.000504	0.00093	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—GHRL—esophageal cancer	0.000497	0.000918	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PFN1—esophageal cancer	0.000495	0.000915	CbGpPWpGaD
Treprostinil—Vomiting—Methotrexate—esophageal cancer	0.000493	0.00187	CcSEcCtD
Treprostinil—Rash—Methotrexate—esophageal cancer	0.000489	0.00186	CcSEcCtD
Treprostinil—Dermatitis—Methotrexate—esophageal cancer	0.000488	0.00186	CcSEcCtD
Treprostinil—PTGIR—Signaling Pathways—CSNK1A1—esophageal cancer	0.000487	0.0009	CbGpPWpGaD
Treprostinil—Headache—Methotrexate—esophageal cancer	0.000486	0.00185	CcSEcCtD
Treprostinil—P2RY12—Hemostasis—NOS2—esophageal cancer	0.000486	0.000897	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—GAPDH—esophageal cancer	0.000485	0.000896	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—PSME1—esophageal cancer	0.000484	0.000894	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—PSME2—esophageal cancer	0.000484	0.000894	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—ANXA1—esophageal cancer	0.000483	0.000892	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—CRABP1—esophageal cancer	0.000481	0.000888	CbGpPWpGaD
Treprostinil—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	0.000479	0.000885	CbGpPWpGaD
Treprostinil—PPARD—Generic Transcription Pathway—CREBBP—esophageal cancer	0.000477	0.000882	CbGpPWpGaD
Treprostinil—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	0.000473	0.000875	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—SST—esophageal cancer	0.00047	0.000867	CbGpPWpGaD
Treprostinil—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000462	0.000854	CbGpPWpGaD
Treprostinil—Nausea—Methotrexate—esophageal cancer	0.00046	0.00175	CcSEcCtD
Treprostinil—PTGIR—Signaling by GPCR—GHRL—esophageal cancer	0.000458	0.000845	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—GNG7—esophageal cancer	0.000457	0.000844	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—NOTCH3—esophageal cancer	0.000456	0.000843	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PFN1—esophageal cancer	0.000456	0.000842	CbGpPWpGaD
Treprostinil—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	0.000449	0.000829	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—NOS2—esophageal cancer	0.000447	0.000826	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—ELMO1—esophageal cancer	0.000445	0.000822	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—CREBBP—esophageal cancer	0.000436	0.000806	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—AKAP13—esophageal cancer	0.000435	0.000803	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—ALDH2—esophageal cancer	0.000428	0.000791	CbGpPWpGaD
Treprostinil—P2RY12—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	0.000426	0.000787	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—ELMO1—esophageal cancer	0.000409	0.000756	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—NOTCH2—esophageal cancer	0.000409	0.000756	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—GSTT1—esophageal cancer	0.000407	0.000753	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—CYP2A6—esophageal cancer	0.000403	0.000744	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—CREBBP—esophageal cancer	0.000401	0.000741	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000401	0.000741	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000401	0.000741	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—AKAP13—esophageal cancer	0.0004	0.000739	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PDE4D—esophageal cancer	0.000398	0.000735	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—NOS3—esophageal cancer	0.00039	0.000721	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PTGS1—esophageal cancer	0.000382	0.000705	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—ENO1—esophageal cancer	0.000382	0.000705	CbGpPWpGaD
Treprostinil—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	0.000382	0.000705	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—GNG7—esophageal cancer	0.000378	0.000699	CbGpPWpGaD
Treprostinil—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000376	0.000695	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PSME1—esophageal cancer	0.000376	0.000695	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PSME2—esophageal cancer	0.000376	0.000695	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000369	0.000682	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000368	0.00068	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PDE4D—esophageal cancer	0.000366	0.000676	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—NOS3—esophageal cancer	0.000359	0.000664	CbGpPWpGaD
Treprostinil—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	0.000359	0.000663	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—XIAP—esophageal cancer	0.000354	0.000655	CbGpPWpGaD
Treprostinil—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000354	0.000654	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—GNG7—esophageal cancer	0.000348	0.000643	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—SMAD4—esophageal cancer	0.000344	0.000635	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CTNNA1—esophageal cancer	0.000335	0.000619	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CXCL2—esophageal cancer	0.000333	0.000616	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000328	0.000607	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—XIAP—esophageal cancer	0.000326	0.000603	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—CYP1B1—esophageal cancer	0.000325	0.0006	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PSME2—esophageal cancer	0.000311	0.000575	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PSME1—esophageal cancer	0.000311	0.000575	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—ANXA1—esophageal cancer	0.00031	0.000572	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CTNNA1—esophageal cancer	0.000308	0.00057	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CXCL2—esophageal cancer	0.000307	0.000567	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—CYP19A1—esophageal cancer	0.000305	0.000564	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—SST—esophageal cancer	0.000301	0.000557	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—EP300—esophageal cancer	0.000297	0.000549	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—NOTCH3—esophageal cancer	0.000294	0.000543	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—GHRL—esophageal cancer	0.000294	0.000543	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—FBXW7—esophageal cancer	0.000289	0.000534	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PSME1—esophageal cancer	0.000286	0.000529	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PSME2—esophageal cancer	0.000286	0.000529	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—ANXA1—esophageal cancer	0.000285	0.000527	CbGpPWpGaD
Treprostinil—PPARD—Generic Transcription Pathway—MYC—esophageal cancer	0.000283	0.000523	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—HMOX1—esophageal cancer	0.000278	0.000514	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—SST—esophageal cancer	0.000277	0.000512	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—EP300—esophageal cancer	0.000273	0.000505	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.000273	0.000505	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—NOTCH3—esophageal cancer	0.00027	0.000499	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—GHRL—esophageal cancer	0.00027	0.000499	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—ABCB1—esophageal cancer	0.000267	0.000494	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—FBXW7—esophageal cancer	0.000266	0.000491	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—NOTCH2—esophageal cancer	0.000263	0.000487	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—NOTCH1—esophageal cancer	0.000253	0.000468	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000249	0.000459	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—NOTCH2—esophageal cancer	0.000242	0.000448	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—TGFBR2—esophageal cancer	0.000234	0.000432	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—CREBBP—esophageal cancer	0.00023	0.000424	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—SMAD4—esophageal cancer	0.000221	0.000409	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—PIK3CA—esophageal cancer	0.00022	0.000406	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000217	0.000401	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—TGFBR2—esophageal cancer	0.000215	0.000397	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—TP53—esophageal cancer	0.000213	0.000393	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—SMAD4—esophageal cancer	0.000204	0.000376	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—PIK3CA—esophageal cancer	0.000202	0.000374	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	0.000202	0.000373	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—TP53—esophageal cancer	0.000196	0.000361	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SLC52A3—esophageal cancer	0.000193	0.000356	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—BLVRB—esophageal cancer	0.000193	0.000356	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—HIF1A—esophageal cancer	0.000181	0.000334	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—CREBBP—esophageal cancer	0.000179	0.00033	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—KDR—esophageal cancer	0.000173	0.00032	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000172	0.000318	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—HIF1A—esophageal cancer	0.000167	0.000308	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CA1—esophageal cancer	0.000164	0.000303	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SLC10A2—esophageal cancer	0.000164	0.000303	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—NOTCH1—esophageal cancer	0.000163	0.000301	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—NOS3—esophageal cancer	0.00016	0.000295	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—KDR—esophageal cancer	0.000159	0.000294	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—NOTCH1—esophageal cancer	0.00015	0.000277	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CA2—esophageal cancer	0.00015	0.000277	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CREBBP—esophageal cancer	0.000148	0.000273	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000147	0.000271	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PTGS2—esophageal cancer	0.000146	0.00027	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—EGFR—esophageal cancer	0.000145	0.000268	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PLCE1—esophageal cancer	0.000139	0.000258	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ADH7—esophageal cancer	0.000139	0.000258	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000139	0.000256	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000138	0.000255	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—MYC—esophageal cancer	0.000136	0.000252	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CREBBP—esophageal cancer	0.000136	0.000251	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—EGFR—esophageal cancer	0.000134	0.000247	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—NOS3—esophageal cancer	0.000132	0.000245	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000128	0.000236	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—PIK3CA—esophageal cancer	0.000126	0.000233	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—ERBB2—esophageal cancer	0.000124	0.000229	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ADH1B—esophageal cancer	0.000122	0.000226	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—NOS3—esophageal cancer	0.000122	0.000225	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—EP300—esophageal cancer	0.000122	0.000225	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—TYMP—esophageal cancer	0.000117	0.000216	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—PIK3CA—esophageal cancer	0.000116	0.000214	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—ERBB2—esophageal cancer	0.000114	0.00021	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP26A1—esophageal cancer	0.000114	0.00021	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ALOX15—esophageal cancer	0.000111	0.000205	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CCND1—esophageal cancer	0.000109	0.000202	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CDKN1A—esophageal cancer	0.000106	0.000195	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTO1—esophageal cancer	0.000106	0.000195	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—TPI1—esophageal cancer	0.000106	0.000195	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ALDOB—esophageal cancer	0.000101	0.000187	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—EP300—esophageal cancer	0.000101	0.000186	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CCND1—esophageal cancer	0.000101	0.000186	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GAPDH—esophageal cancer	9.75e-05	0.00018	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CDKN1A—esophageal cancer	9.74e-05	0.00018	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CRABP1—esophageal cancer	9.66e-05	0.000178	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—EP300—esophageal cancer	9.27e-05	0.000171	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GNG7—esophageal cancer	9.19e-05	0.00017	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PIK3CA—esophageal cancer	9e-05	0.000166	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—MYC—esophageal cancer	8.77e-05	0.000162	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ALDH2—esophageal cancer	8.61e-05	0.000159	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—EGFR—esophageal cancer	8.58e-05	0.000159	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTT1—esophageal cancer	8.19e-05	0.000151	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP2A6—esophageal cancer	8.1e-05	0.00015	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—MYC—esophageal cancer	8.07e-05	0.000149	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	8.07e-05	0.000149	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—EGFR—esophageal cancer	7.9e-05	0.000146	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ENO1—esophageal cancer	7.68e-05	0.000142	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PTGS1—esophageal cancer	7.68e-05	0.000142	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PSME1—esophageal cancer	7.56e-05	0.00014	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PSME2—esophageal cancer	7.56e-05	0.00014	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PIK3CA—esophageal cancer	7.45e-05	0.000138	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—TP53—esophageal cancer	7.21e-05	0.000133	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PIK3CA—esophageal cancer	6.85e-05	0.000127	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—TP53—esophageal cancer	6.63e-05	0.000122	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	6.61e-05	0.000122	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP1B1—esophageal cancer	6.53e-05	0.000121	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP19A1—esophageal cancer	6.14e-05	0.000113	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—HMOX1—esophageal cancer	5.6e-05	0.000103	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.49e-05	0.000101	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ABCB1—esophageal cancer	5.37e-05	9.93e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.06e-05	7.51e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CREBBP—esophageal cancer	3.59e-05	6.64e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NOS3—esophageal cancer	3.22e-05	5.94e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PTGS2—esophageal cancer	2.94e-05	5.43e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—EP300—esophageal cancer	2.45e-05	4.52e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.81e-05	3.34e-05	CbGpPWpGaD
